Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually ...
A drug mimicking the hormone progesterone has anti-cancer activity when used together with conventional anti-estrogen ...
SurvivorNet on MSN
The evERA Trial: A Promising Treatment Option For Patients With Estrogen Receptor-Positive (ER+), HER2-Negative (HER2-) Breast Cancer
The evERA breast cancer trial marks a turning point for some patients with a specific type of advanced breast cancer known as ...
Hormone therapies have played a major role in improving survival for patients with ER+ breast cancer [1]. By blocking or reducing estrogen’s impact, these treatments slow the cancer’s growth and help ...
A study led by researchers at the Hospital del Mar Research Institute advances one of the most significant milestones in breast cancer treatment, making immunotherapy effective against the most common ...
FDA removes black box warnings for most MHT products, reflecting evidence that breast cancer risk varies by formulation, ...
CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback